We recently demonstrated that Venezuelan equine encephalitis virus-based replicon particle (VRPs) encoding tumor antigens could break tolerance in the immunomodulatory environment of advanced cancer. We hypothesized that local injection of VRP-expressing interleukin-12 (IL-12) at the site of injections of VRP-based cancer vaccines would enhance the tumor-antigen-speciWc T cell and antibody responses and antitumor eYcacy. Mice were immunized with VRP encoding the human tumorassociated antigen, carcinoembryonic antigen (CEA) (VRP-CEA(6D)), and VRP-IL-12 was also administered at the same site or at a distant location. CEA-speciWc T cell and antibody responses were measured. To determine antitumor activity, mice were implanted with MC38-CEA-2 cells and immunized with VRP-CEA with and without VRP-IL-12, and tumor growth and mouse survival were measured. VRP-IL-12 greatly enhanced CEA-speciWc T cell and antibody responses when combined with VRP-CEA(6D) vaccination. VRP-IL-12 was superior to IL-12 protein at enhancing immune responses. Vaccination with VRP-CEA(6D) plus VRP-IL-12 was superior to VRP-CEA(6D) or VRP-IL-12 alone in inducing antitumor activity and prolonging survival in tumor-bearing mice. Importantly, local injection of VRP-IL-12 at the VRP-CEA(6D) injection site provided more potent activation of CEA-speciWc immune responses than that of VRP-IL-12 injected at a distant site from the VRP-CEA injections. Together, this study shows that VRP-IL-12 enhances vaccination with VRP-CEA(6D) and was more eVective at activating CEAspeciWc T cell responses when locally expressed at the vaccine site. Clinical trials evaluating the adjuvant eVect of VRP-IL-12 at enhancing the immunogenicity of cancer vaccines are warranted.
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Background
Viral vectors that encode tumor-associated antigens (TAAs) are attractive for cancer immunotherapy because they may be engineered to deliver whole antigens containing multiple CD4+ and CD8+ T cells epitopes and to produce cytokine [1, 2] and immunomodulatory molecules that enhance immune responses. They also infect dendritic cells (DC) and induce DC maturation through both TLR-dependent and -independent pathways, resulting in the upregulation of co-stimulatory molecules and the secretion of Th1-inducing cytokines [3, 4] .
Among the many recombinant viral vectors that have been developed, Venezuelan equine encephalitis (VEE) virus-like replicon particles (VRPs) possess intriguing characteristics including signiWcant expression of the inserted gene in infected cells [5] , induction of both humoral and cell-mediated immunity [6] , potential for repeated immunizations despite induction of vector-speciWc neutralizing antibody, and potential tropism for DCs. VRP infects both murine and human DC [7, 8] , and VRP-transduced DCs eYciently process and present VRP-encoded antigens, leading to robust proliferation of antigen-speciWc T cells and acquisition of eVector functions. These in vitro and in vivo eVects are thought to be due in part to the maturation of DC by VRP including the upregulation of co-stimulatory molecules CD40, CD80, CD86, the maturation marker CD83 [8, 9] , and the secretion of proinXammatory cytokines including IFN-gamma, TNF-alpha, IL-6, and IL12p70 [10] . We have generated a recombinant VRP expressing a well-characterized human tumor-associated antigen [carcinoembryonic antigen (CEA)] (VRP-CEA(6D)) and demonstrated that it was eVective in inducing CEA-speciWc immune responses in cancer patients [11] . Nonetheless, the modest magnitude of the immune response and the requirement for multiple immunizations suggested that these vectors could be enhanced.
The use of immunostimulatory cytokines to enhance immune responses has been well established. Many of these were systematically analyzed in the context of gene-modiWed tumor vaccines, in which the many innate immune stimulatory signals inherent to viral vectors were not present [12] . We hypothesized that IL-12, delivered in the context of the potent immune stimulatory signals provided by VRP, might enhance antitumor immune responses when combined with VRP-expressing CEA in murine tumor models. IL-12 plays a key role in the diVerentiation of type-1 helper T cells (Th1) and enhances CTL responses through its eVects on inducing IFN-production [13] . Indeed, in preliminary studies, we downselected from a series of novel recombinant alphaviral VRP-expressing cytokines and growth factors and identiWed that VRP-expressing IL-12 (VRP-IL-12) was the most potent in enhancing adaptive immune responses to CEA (Peter Bergslund, unpublished observations) when delivered in combination with VRPexpressing CEA. In the current study, we performed a more detailed analysis of the eVect of the VRP-IL-12 co-injected with VRP-CEA compared with VRP-IL-12 injected at a distance on enhancing immune responses and antitumor immunity in mice harboring CEA-expressing colon cancer.
Materials and methods
Reagents
Recombinant murine IL-12 protein was purchased from BioVision (Mountain View, CA). Recombinant inXuenza hemagglutinin (HA) protein and carcinoembryonic antigen (CEA(6D)) protein were purchased from Protein Sciences (Meriden, CT).
PE-labeled anti-mouse CD80, anti-mouse CD86, antimouse IL-12, FITC-labeled anti-mouse CD14, and APClabeled anti-mouse I-A/I-E monoclonal antibodies were all purchased from BioLegend (San Diego, CA).
Cell lines
The murine colon adenocarcinoma cell line, MC38-CEA-2, expressing human CEA was kindly provided by Dr. JeVrey Schlom (National Cancer Institute) [14] . Cells were cultured in the complete Dulbecco's modiWed Eagle's medium (Invitrogen, Carlsbad, CA) supplemented with 10 % fetal bovine serum. Mice C57BL/6 mice and BALB/c mice were purchased from Jackson Labs (Bar Harbor, ME) and bred in the Duke Comprehensive Cancer Center Isolation Facility. All animal studies described were approved by the Duke University Medical Center Institutional Animal Care and Use Committee, in accordance with guidelines published by the Commission on Life Sciences of the National Research Council. For in vivo tumor model, C57BL/6 mice were used with MC38-CEA-2 cell line that has C57BL/6 background.
Generation of VRP
Generation of VRP-CEA(6D) (an alphaviral replicon particle (VRP) expressing the tumor antigen CEA(6D) in which an Asn to Asp substitution has been made in the HLA A2-restricted epitope within the CEA gene that results in enhanced T cell receptor recognition) was as described elsewhere [11, 15, 16] . The CEA replicon map is shown in Supplementary Figure 1A .
To generate VRP-IL-12, a replicon plasmid was constructed by cloning the p40 and p35 subunit genes in frame separated by a short linker sequence derived from the elastin gene. This was done by subcloning the p40-p35 gene from mIL-12elasti p40::p35 (Invivogen, San Diego, CA) using primers designed to contain Xanking EcoRV and AscI restriction sites. The murine IL-12 gene was then cloned into the pERK3 replicon vector as an EcoRV/AscI fragment. Replicon plasmids containing the p40 and p35 genes alone were constructed using the same cloning method. VRPs were produced as previously described [15, 16] .
Infection of cells with VRP-IL-12
Murine dendritic cells were generated from bone marrow of C57BL/6 mice by culturing cells in the presence of murine GM-CSF (10 ng/mL, Invitrogen) and IL-4 (10 ng/mL, Invitrogen) for 10 days. DCs were infected with VRP-IL-12 at moi 10 or moi 100, or empty vector (VRP-Empty) at moi 100. For positive control sample, lipopolysaccharide (1 g/mL, Sigma, St. Louis, MO) was added to the medium. The DCs were incubated for 18-24 h, and DC expression and secretion of IL-12 were analyzed by Xow cytometry and ELISA, respectively. 
IL-12 ELISA
Culture supernatants from VRP-IL-12-infected DC or VRP-Empty-infected DC were analyzed for IL-12 p70 level using Quantikine mouse IL-12 p70 ELISA kit (R&D Systems, Minneapolis, MN).
Vaccination of mice
For vaccine immunogenicity studies, varying doses of VRP-CEA(6D) (and in some experiments, CEA protein) were injected into the footpad of mice (20 microliters per foot pad), twice, 3 weeks apart. Mice were killed 7 days after the second immunization, and serum and splenocytes were collected to assess for anti-CEA antibody by ELISA and CEA-speciWc lymphocytes using an IFN ELISPOT assay (Mabtech) as described below. In some experiments, VRP-IL-12 (at various IUs) was co-injected with the VRP-CEA(6D). In other experiments, IL-12 protein (1, 10, 100 ng/mouse) was co-injected.
Comparison of co-injection and contralateral injection of VRP-IL-12 and VRP-CEA(6D)
Mice were vaccinated with VRP-CEA(6D) (5 £ 10 7 I.U) and VRP-IL-12 (5 £ 10 6 I.U) by co-injection of a mixture of these two vectors, or by separate injection of VRP-CEA(6D) and VRP-IL-12 into diVerent limbs (contralateral injection). As controls, mice were vaccinated with VRP-CEA(6D) alone, VRP-IL-12 alone, or saline. Two weeks after the vaccination, anti-CEA immune response was analyzed by an IFN ELISPOT assay using splenocytes.
ELISA for anti-CEA antibodies Mouse sera were collected and frozen at ¡80°C until use. Microtiter plates (Immulon 4HBX, Thermo ScientiWc, Rochester, NY) were coated with CEA peptide mix or CMVpp65 peptide mix (BD Bioscience) at concentration of 2.6 g/mL. Plates were incubated at 4°C overnight, washed with PBS, and blocked with 1 %BSA in PBS for 1 h. Thawed sera were diluted with the titration of 1:40-1:320,000 with 1 % BSA in PBS, added to each well and incubated for 2 h. Sera from naïve mice (saline injected mice) were used as a negative control. Plates were developed with 100 L of a 1:2,500 dilution of sheep alkaline phosphatase-conjugated anti-mouse IgG antibody (Jackson Immunoresearch Laboratories, West Grove, PA) for 1 h at 37°C. Plates were washed three times, and 50 L per well of the pNPP substrate solution (5 mg/mL, p-nitrophenyl phosphate, Sigma) was added to each well. The reaction was stopped by adding 50 L per well of NaOH solution. Absorbance was measured at 405 nm.
ELISpot analysis
Mouse IFN ELISPOT assay (Mabtech Inc., Cincinnati, OH) was performed according to the manufacturer's instructions. Splenocytes (500,000 cells/well) were incubated in RPMI-1640 medium (Invitrogen) supplemented with 10 % fetal bovine serum, and CMVpp65 peptide mix or CEA peptide mix (2.6 g/mL: BD Bioscience, San Jose, CA) was used as a stimulating antigen. Peptide mixes consist of 15-mers overlapping by 11 amino acids and cover the entire protein sequence. HIV peptide mix (BD Bioscience) was used as a negative control, and a mixture of PMA (50 ng/mL) and Ionomycin (1 g/mL) as a positive control of the assay.
EVect of VRP-IL-12 vaccine in MC38 tumor-bearing mice
To analyze functional antitumor responses in vivo, C57BL/ 6 mice were inoculated with MC38-CEA-2 tumor cells (2.5 M cells/mouse) into the Xank, and 5 days later, mice were randomized into 4 groups (10 mice/group): A, VRP-CEA + VRP-IL-12; B, VRP-Empty + VRP-IL-12; C, VRP-CEA + VRP-Empty; and D, VRP-Empty only. The VRP-CEA(6D) and VRP-IL-12 (5 £ 10 7 I.U./mouse) were administered at 5 £ 10 7 I.U./mouse. The total amount of VRP vectors inoculated into each mouse at each injection time point was intended to total 1 £ 10 8 I.U., and thus, VRP-Empty vector was added to the vaccine inocula that contained only a single vector to adjust to a total number of 1 £ 10 8 I.U. Two weeks after the Wrst vaccination (on day 19), the same combination of vaccine was re-injected into the footpads. Tumor size was measured twice weekly. Mice were euthanized when their tumor size exceeded 2,000 mm 3 . Survival of mice was also monitored until all the groups had less than 50 % survival.
Statistical analysis
For the ELISpot assays and ELISA, diVerences in IFNproduction and antibody binding, respectively, were analyzed using the Student's t test. The diVerences in tumor volumes for each vaccine strategy compared to control (VRP-Empty only) were assessed by Student's t test at each time point of tumor volume measurements. For the analysis of survival, Kaplan-Meier survival estimates were performed to depict the survival curves by treatment. The log rank test was performed to compare the survival between diVerent treatment groups. For all experiments, diVerences at p < 0.05 were considered statistically signiWcant.
Results
Infection of cells with VRP-CEA(6D) induces CEA expression with appropriate translocation and post-translational modiWcation
To test the ability of the VRP-CEA(6D) to infect cells and express CEA, we infected Vero cells with VRP-CEA(6D) and evaluated CEA expression by immunoXuorescent staining or Xow cytometry with anti-CEA mAb. CEA staining was localized intracellularly as well as on the plasma membrane. The non-cytoplasmic, reticular pattern of the intracellular signal was consistent with biosynthesis through ER-Golgi for secretion ( Supplementary Fig. 1B) . CEA expression by VRP-CEA-infected mouse DC was also demonstrated by Xow cytometry (data not shown). We conWrmed that full-length CEA protein was expressed from the CEA replicon and yielded a shorter fragment consistent with the putative 76.8 kDa molecular weight protein when deglycosylated ( Supplementary Fig. 1C ). These data demonstrate that CEA is appropriately translocated and posttranslationally modiWed, and transported through the Golgi to the plasma membrane. Immune monitoring assays were performed 7 days after the second immunization. Seven or eight mice were vaccinated for each group. a Anti-CEA antibody titers in the sera were analyzed by ELISA. Sera were diluted with the titration of 1:40 to 1:320,000 with 1 % BSA in PBS and incubated for 2 h in CEA protein-coated microtiter plate. Sera from naïve mice (saline injected mice) were used as a negative control. Plates were incubated with alkaline phosphatase-conjugated anti-mouse IgG antibody and then developed with pNPP substrate solution. The reaction was stopped by NaOH solution, and absorbance was measured at 405 nm. Reciprocal titers of anti-CEA antibody are shown. Bar shows mean values for each group. b Mouse IFN ELI-SPOT assay was performed with splenocytes (1 £ 10 6 cells/well). CEA peptide mix (2.6 g/mL: BD Bioscience, San Jose, CA) was used as a stimulating antigen. Each dot shows the number of IFN--positive spots per 1 £ 10 6 splenocytes for each mouse. Bars shows mean values for each group. *p < 0.05, **p < 0.01, ***p < 0.001 
VRP-IL-12 infection of DC leads to cytokine secretion and maturation of DC
We have previously shown that IL-12 is a biomarker for DC maturation in a subset of DC [17] . Therefore, we analyzed murine bone marrow-derived DC infected with VRP-IL-12 for IL-12 expression and for maturation markers. As shown in Fig. 2a , VRP-IL-12 infection of DC induced IL-12 secretion greater than DC stimulated with lipopolysaccharide (LPS), while VRP-Empty infection had no eVect on IL-12 production by DC. Intracellular staining conWrmed IL-12 production by CD14-negative/MHC class II-positive DC after 24 and 48 h of infection (Fig. 2b) . Maturation markers (CD80, CD86) were analyzed by Xow cytometry. Interestingly, both VRP-Empty vector (moi 100) and VRP-IL-12 (moi 100) enhanced CD86 expression following infection ( Supplementary Fig. 3 ). These data suggest that VRP vectors upregulate CD86, but only those vectors containing IL-12 caused IL-12 secretion. In order to determine whether VRP-IL-12 could enhance the immune response to VRP-CEA(6D), we administered either VRP-CEA(6D) (5 £ 10 5 I.U.) or VRP-IL-12 (ranging from 5 £ 10 1 to 5 £ 10 7 I.U.) or a mixture of the two vectors. Study groups receiving more than 5 £ 10 2 I.U. of VRP-IL-12 displayed signiWcantly higher levels of IFNgamma-secreting antigen-speciWc lymphocyte responses than mice immunized with VRP-CEA(6D) alone (Fig. 3a) . When coadministered with VRP-CEA(6D) (5 £ 10 5 I.U.), the strongest cellular immune responses against CEA were seen in mice receiving 5 £ 10 5 I.U. of VRP-IL-12. The enhancement in cellular immune responses was not due merely to an increase in the VRP-delivered replicons since mock adjuvants consisting of empty VRP (VRP-Empty) did not enhance the CEA-speciWc responses to the VRP-CEA(6D) vaccine component (Fig. 3a) .
Unexpectedly, higher levels of VRP-IL-12 appeared to cause a signiWcant decrease in CEA-speciWc T cell responses. In order to rule out the possibility that VRP-IL-12 could be immunosuppressive at the highest dose (5 £ 10 7 I.U.), we immunized mice with VRP-CEA(6D) and VRP-IL-12, at escalating doses of both components from 5 £ 10 4 up to 5 £ 10 7 I.U., while keeping the ratio between them constant (Fig. 3b, left side) . Dose-dependent increases in the levels of antigen-speciWc T cell responses, even up to the highest dosage levels tested (Fig. 3b) , were observed. These results suggest that the inhibitory eVects of IL-12 only manifest themselves when coadministered together with a signiWcantly lower dose of CEA-VRP.
VRP-IL-12 induces a more potent immune response than IL-12 protein
In order to compare the adjuvant activity of VRP-IL-12 with IL-12 protein, mice were immunized with VRP-CEA(6D) (5 £ 10 5 I.U) combined with recombinant baculovirus-produced IL-12 protein at escalating doses. The dosage levels ranged from 1 ng to 100 ng and were chosen because Vero cells (5 £ 10 5 ) infected with 5 £ 10 5 I.U. of VRP-IL-12 were found to produce approximately 10 ng of IL-12 (data not shown). As seen in Fig. 4a , recombinant soluble IL-12 protein did not augment the anti-CEA immune responses at the doses used, whereas VRP-IL-12 displayed signiWcant adjuvant activity.
We also carried out experiments to assess the ability of VRP-IL-12 to adjuvant immune responses to recombinant CEA protein. This study showed that 5 £ 10 5 IU of VRP-IL-12 enhanced the humoral as well as cell-mediated anti-CEA immune responses, indicating wider applicability of VRP-IL-12 as an adjuvant for vaccine with various platforms ( Supplementary Fig. 4) .
To determine whether enhancement of antigen-speciWc immune response induced by VRP-IL-12 is a local eVect at the injection site or a systemic eVect of generated IL-12, mice were vaccinated with VRP-CEA(6D) and VRP-IL-12 by co-injection or contralateral injection. Although there SFC/1e6 lymphocytes * * * * * * * * * * * was a vaccine adjuvant eVect from the release of IL-12 systemically as can be seen by contralateral injection of VRP-IL12 and VRP-CEA(6D) (Fig. 4b) , co-injection induced a stronger enhancement of CEA-speciWc T cell responses than contralateral injection did, suggesting that the local eVects of the IL-12 predominate over the systemic eVect of IL-12 derived from the VRP-IL-12.
VRP-IL-12 enhances antitumor responses against VRP-CEA(6D)
To assess the adjuvant eVect of VRP-IL-12 on therapeutic cancer vaccines, we compared VRP-CEA(6D) vaccine with or without VRP-IL-12 in C57BL/6 mice implanted with MC38-CEA-2, a murine colon cancer cell line that expresses human CEA antigen at low level. Mice (10 per group) were inoculated with 2.5 £ 10 6 MC38-CEA-2 cells on day 0, and on day 5 and day 19, vaccination was performed with VRP-CEA(6D), VRP-IL-12, the combination of the two and VRP-Empty as a control. No toxicity was observed in these animals. We analyzed the serum level of IL-12 in mice that were treated with a single injection of VRP-IL12 (5 £ 10 7 I.U.) by ELISA. We conWrmed signiWcant serum concentrations of IL-12 a week after VRP-IL12 injection (approximately 25 ng/mL on day 1 and 5 ng/mL on day 7).
As expected, ELISPOT analysis of splenocytes and ELISA of serum showed enhanced CEA-speciWc responses from tumor-bearing mice vaccinated with VRP-CEA(6D)/ VRP-IL-12, which was superior to the mice vaccinated with VRP-CEA(6D) alone (Fig. 5a, b) . VRP-IL-12 treatment alone did not induce enhanced CEA-speciWc cellular and humoral responses. These data suggest that the VRP-IL-12 may enhance immune responses in the tumor-bearing host.
Regarding antitumor eVects in this model of established disease, signiWcantly lower tumor growth was observed when VRP-IL-12 was coadministered with VRP-CEA compared with VRP-CEA alone (Fig. 6a) . In addition, there was a trend for a reduction in tumor growth for the combination of VRP-CEA and VRP-IL-12 compared with VRP-IL-12 alone. The experiment was repeated twice, with very similar trend, although the diVerence between VRP-IL-12 alone and the combination of VRP-CEA(6D) and VRP-IL-12 at time point of day 27 has a p value of 0.15.
Survival was monitored until all groups had fewer than 50 % mice remaining alive. No metastatic lesions were observed when mice were euthanized. Kaplan-Meier survival estimates of all of the data are shown in Fig. 6b . The co-injection of VRP-CEA(6D) and VRP-IL-12 resulted in signiWcantly better survival compared with VRP-CEA alone and VRP-IL-12 alone (p = 0.011).
Discussion
Viral replicon particles (VRPs) represent a novel strategy to simultaneously deliver both TAAs and a strong maturation signal to antigen-presenting cells such as DCs. Nonetheless, it is likely that this strategy will be applied in cancer patients that may have signiWcant immunoregulatory dysregulation due to their cancer burden, and strategies to augment immune responses may be critical for eYcacy. Therefore, an evaluation of additional signals that could enhance immune responses to these recombinant viral vectors was undertaken. We were most interested in IL-12 because IL-12 plays a key role in the diVerentiation of type-1 helper T (Th1)cells from uncommitted T (Th0) cells during an immune response, enhances CTL responses (through its eVects on inducing IFN-production), and enhances NK cell function [18] [19] [20] [21] .
In human clinical trials of various malignancies, systemic IL-12 has been administered alone [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Systemic IL-12 has also been utilized in combination with cancer vaccines including a gp100 human melanoma peptide vaccine [32] . Although there has been considerable negative data with the use of IL-12 as a vaccine adjuvant, two studies have demonstrated enhancement of immune responses to peptide vaccines in melanoma [33, 34] . The use of systemic rhIL-12, however, is limited by toxicity and tachyphylaxis. Toxicity (fatigue, hypotension, hepatic enzyme elevation, hemolytic anemia, gastrointestinal bleeding, lymphopenia, and neutropenia) is dose and schedule dependent, likely related to the rapid elevation of IFN-plasma levels. Several deaths were reported during the initial studies with IL-12 given on a more intense schedule [35] . Therefore, coadministration along with a vaccine may be preferred to avoid systemic toxicity of IL-12 protein. We observed signiWcant concentrations of IL-12 in mouse sera a week after VRP-IL12 injection; however, these serum concentrations of IL-12 are lower than would be expected with systemic treatment with recombinant IL-12 protein (50-70 ng/mL; 5 h after subcutaneous injection of 1 g IL-12 protein) [36] . Furthermore, the VRP-IL-12 vector is expected to induce a slow rise of IL-12 in the serum compared to protein administration, because of the time required for delivery of the transgene and protein production and secretion by the target cells. Thus, toxicities induced by VRP-IL12 are expected to be much less than systemic injection of recombinant IL-12. Indeed, we did not observe signiWcant toxicity in the mice in our studies. In addition, a strategy to prolong IL-12 production at the site of the vaccine could prolong the immune response. In fact, our mouse experiments demonstrated that coadministration of VRP-IL-12 with VRP-CEA(6D) induced signiWcantly stronger anti-CEA immune response than co-injection of recombinant IL-12 protein (Fig. 4a) , contralateral injection of these two vectors, or vaccination with VRP-CEA(6D) alone (Fig. 4b) , suggesting the beneWt of local delivery of VRP-IL-12. Co-injection of VRP-IL12 is more eYcient than recombinant IL-12 to stimulate CTL induction by VRP-CEA(6D)-infected DC at the lymph nodes, probably because ongoing IL-12 production by VRP-IL12-infected cells would have a longer paracrine eVect than recombinant IL-12 protein, which would diVuse away, lowering the local concentrations over time.
This Wnding of enhanced immune response with codelivery of IL-12 was intriguing particularly with the VEEbased vaccine, as these particular vectors have been reported to infect and mature DC, but cytokine production by the VEE-infected DC was modest [8] . In fact, previously, we noted that only a small subset of DC can produce high levels of IL-12, despite multiple signals [17] . Consequently, we examined the use of VRP-IL-12 to confer IL-12 production on human and mouse DC and demonstrated this was vastly superior to VRP infection alone in producing high levels of IL-12.
Regarding our choice of model to test the eVects of VRP-IL-12 on antitumor immune responses, we used the MC38-CEA-2 cell line as the tumor target, wild-type mice (C57BL/6), and VRP-CEA(6D) as the vaccine. We chose the C57BL/6 mice rather than CEA-transgenic mice because the MC38 cell line was derived from mice with a C57BL/6 background, whereas the commercially available CEA-transgenic models are of a BALB/c background. The MC38-CEA-2 cell line expresses CEA at low levels, which could explain the low antitumor activity of the VRP-CEA(6D) vaccine alone; however, we were most interested in the adjuvant eVect of IL-12 and, therefore, wished to use a model with more moderate antitumor responses to the vaccine as could be observed in patients with cancer.
We then wished to determine the ideal conditions for combining the VRP-IL-12 with the VRP-CEA(6D). There was a range of ratios of the two vectors that was eVective in inducing CEA-speciWc immune responses (Fig. 3a) , and subsequently, we found that the inhibitory eVects of IL-12 only manifest themselves when coadministered together with a signiWcantly lower dose of vaccine VRP (Fig. 3b) . The mechanism for this eVect is not clear but might be a result of interferon released in response to the vaccination resulting in silencing of the administered VRP, which would notably aVect the VRP presents at the lower titer. These results further indicate that a range of ratios between the antigen and the adjuvant VRP components should be tested, and ratios shown to be eVective should be used in combination with other vaccines as a potent and promising adjuvant.
Importantly, the combination of VRP-CEA(6D) and VRP-IL-12 signiWcantly enhanced anti-CEA response and antitumor response compared to VRP-CEA(6D) alone and prolonged survival of mice compared to VRP-CEA(6D) vaccine alone or VRP-IL-12 alone. These results clearly demonstrate beneWcial adjuvant eVect of VRP-IL-12 for cancer vaccines.
In summary, we screened a variety of cytokines and hematopoietic growth factors that were co-delivered in combination with VRP-based vaccines and found that IL-12 was most potent in enhancing antigen-speciWc immune responses and antitumor responses. We found that a clinically feasible ratio of IL-12 and antigen delivery could be identiWed in preclinical studies. Enhancing VEE-based anticancer vaccines by co-delivery with VEE expressing IL-12 may be an important enhancement of cancer immunotherapy to be tested in clinical trials. 35 . Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB et al (1997) EVects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90:2541-2548 36. Rakhit A, Yeon MM, Ferrante J, Fettner S, Nadeau R, Motzer R et al (1999) Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice. Clin Pharmacol Ther 65:615-629
